BioArctic AB (publ) (B9A.F)
- Previous Close
18.06 - Open
17.93 - Bid 17.83 x --
- Ask 18.20 x --
- Day's Range
17.93 - 17.93 - 52 Week Range
11.94 - 23.10 - Volume
500 - Avg. Volume
22 - Market Cap (intraday)
1.603B - Beta (5Y Monthly) -0.74
- PE Ratio (TTM)
19.28 - EPS (TTM)
0.93 - Earnings Date Aug 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 10, 2019
- 1y Target Est
--
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
www.bioarctic.seRecent News: B9A.F
View MorePerformance Overview: B9A.F
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is ^OMX (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: B9A.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: B9A.F
View MoreValuation Measures
Market Cap
1.60B
Enterprise Value
1.54B
Trailing P/E
19.29
Forward P/E
17.45
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.47
Price/Book (mrq)
8.99
Enterprise Value/Revenue
11.09
Enterprise Value/EBITDA
17.75
Financial Highlights
Profitability and Income Statement
Profit Margin
59.44%
Return on Assets (ttm)
35.28%
Return on Equity (ttm)
61.64%
Revenue (ttm)
1.52B
Net Income Avi to Common (ttm)
901.96M
Diluted EPS (ttm)
0.93
Balance Sheet and Cash Flow
Total Cash (mrq)
788.57M
Total Debt/Equity (mrq)
2.64%
Levered Free Cash Flow (ttm)
-54.76M